Risk factors for the mortality of hemodialysis patients with COVID-19 in northern Hunan province, China.

Risk factors for the mortality of hemodialysis patients with COVID-19 in northern Hunan province, China.

Publication date: Jan 16, 2025

Exploring the risk factors for mortality of hemodialysis patients undergoing COVID-19 and the changes in mortality before and after the opening of the epidemic in northern Hunan province, China. We analyzed 230 hemodialysis patients with COVID-19 in the Yiyang Central Hospital from November 01, 2022 to February 28, 2023. Demographic data, laboratory data and public diseases were collected. Cox regression analysis was used to identify risk factors and independent predictors of mortality. The receiver operating characteristic (ROC) curve was used to determine the diagnostic value of risk factors in hemodialysis COVID-19 patients. The average duration of the disease was 12. 53 days. The mortality rate in our cohort was 28. 70%. Independent predictors of mortality in our cohort were: age (hazard ratio [HR] 1. 09; 95% confidence interval [CI], 1. 05-1. 14; P 

Open Access PDF

Concepts Keywords
53days Adult
China Age Factors
Epidemic Aged
February China
Hemodialysis COVID-19
COVID-19
Female
Hemodialysis
Humans
Kidney Failure, Chronic
Leukocyte Count
Male
Middle Aged
Mortality
Neutrophils
Procalcitonin
Procalcitonin
Prognosis
Renal Dialysis
Retrospective Studies
Risk Factors
ROC Curve
SARS-CoV-2

Semantics

Type Source Name
disease MESH COVID-19
drug DRUGBANK Saquinavir
pathway REACTOME Reproduction
disease IDO blood
disease IDO cell
disease MESH respiratory infections
disease MESH chronic diseases
disease MESH hypertension
pathway REACTOME Immune System
drug DRUGBANK Coenzyme M
disease MESH death
disease IDO country
disease MESH cerebrovascular diseases
disease MESH pneumonia
disease MESH hypoxia
disease MESH syndrome
disease MESH multiple organ failure
drug DRUGBANK Methionine
disease IDO nucleic acid
disease MESH congenital heart disease
drug DRUGBANK Calcium Phosphate
drug DRUGBANK Parathyroid hormone
drug DRUGBANK Cholesterol
drug DRUGBANK Probucol
drug DRUGBANK Nesiritide
drug DRUGBANK Trinitrotoluene
disease MESH diabetes mellitus
disease MESH chronic obstructive pulmonary disease
drug DRUGBANK L-Valine
disease MESH cerebrovascular accident
drug DRUGBANK Esomeprazole
drug DRUGBANK Creatinine
drug DRUGBANK Phosphate ion
drug DRUGBANK Oxygen
drug DRUGBANK Calcium
disease MESH infection
disease IDO bacteria
disease MESH viral infection
disease MESH lymphocytopenia
disease IDO process
disease MESH inflammation
disease IDO pathogen
disease MESH bacterial infections
disease MESH ischemic heart disease
disease MESH coronavirus infection
disease IDO drug susceptibility
drug DRUGBANK Ritonavir
disease MESH Critically ill
disease MESH respiratory failure
disease MESH complications
disease MESH shock
disease MESH acute kidney injury
disease MESH thromboembolism
drug DRUGBANK Polyethylene glycol
disease MESH aids
disease IDO intervention
disease MESH uremia
disease IDO immune response
disease MESH frailty
drug DRUGBANK L-Asparagine
disease MESH sepsis
disease MESH tics
drug DRUGBANK Dexamethasone
disease MESH Kidney Failure Chronic

Original Article

(Visited 2 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *